Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00158132 · ClinicalTrials.gov registry record · Phase 2

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

A Phase 2 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 2
Development phase
199
Enrollment target

NCT00158132: Completed Phase 2 study, sponsored by University of Pennsylvania.

NCT00158132 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 199 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00158132, a Phase 2 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 2
Development phase
199 participants
Enrollment target

Study Summary

Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Amantadine, a medication that improves muscle control, and propranolol, a medication that lowers blood pressure, may be useful in treating cocaine addiction in individuals with severe cocaine withdrawal symptoms. This study will evaluate the effectiveness of amantadine and propranolol in preventing drug relapse among cocaine addicts.

Interventions

  • DRUG Placebo
  • DRUG Propranolol
  • DRUG Amantadine

Trial Details

FieldValue
Enrollment Target 199 participants
Start Date 1999-09
Est. Completion 2006-02
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT00158132

The ClinicalTrials.gov registry entry for NCT00158132 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00158132 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00158132 about?

NCT00158132 is a clinical study titled "Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2". Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Amantadine, a medication that improves muscle control, and propranolol, a medication that lowers blood pressure, may be useful in treating cocaine addiction in individuals with severe cocaine wi...

What is the current status of trial NCT00158132?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 1999-09. Estimated completion is 2006-02.

What interventions are being tested in trial NCT00158132?

The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG), Amantadine (DRUG).

Who is sponsoring clinical trial NCT00158132?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.